All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

ExCellThera's Zemcelpro (UM171 Cell Therapy) receives EC approval for blood cancer patients lacking suitable donors
Cell therapy, cancer, haematopoietic stem cell therapy, blood cancer, cord blood expansion, stem cell transplantation - Read more

Sinovac's tetanus vaccine with nano-adjuvant technology receives approval from China's NMPA
Vaccine, infectious disease, tetanus, aluminum adjuvant, monoclonal antibody - Read more

EC approves Bio-Thera's USYMRO (ustekinumab), IL-12/23 inhibitor biosimilar for psoriasis and other inflammatory conditions
Antibody, autoimmune, biosimilar, monoclonal antibody, ustekinumab, regulatory approval - Read more

THE GOOD
Business Development & Partnerships

MannKind, United Therapeutics expand collaboration for second inhaled therapy with $5M upfront, $35M in milestones
Licensing deal, pulmonary hypertension, drug formulation, milestone payments, respiratory - Read more

Novo Nordisk partners with 9amHealth, adding virtual obesity care to NovoCare platform for GLP-1 patients
Commercialization, digital health, cardiometabolic, US, telehealth - Read more

PRESENTED BY PROMOVEO HEALTH
Contract Sales Reps. Half the Budget. Double the Impact.

Stretching your commercial budget?

Get two flex-time reps for the price of one full-time with Promoveo Health.

We build agile field teams that scale up or down based on your brand’s needs — fast.

See how flexible can work - click here to learn more.

✅ More Good News ✅

THE GOOD
Clinical Trials

RemeGen and Vor's telitacicept meets Ph3 endpoint in IgA nephropathy, reducing kidney damage marker by 55%
Protein therapy, autoimmune, fusion protein, IgA nephropathy, kidney disease, Sjögren's disease - Read more

Eli Lilly's Verzenio shows survival benefit in Ph3 study for high-risk HR+/HER2- early breast cancer
Small molecule, cancer, CDK4/6 inhibitor, breast cancer, hormone receptor-positive, HER2-negative - Read more

Antiva's ABI-2280 shows 46% HPV clearance in Ph1b/2 trial for cervical human papillomavirus infection
Small molecule, infectious disease, antiviral, HPV, cervical cancer prevention, topical therapy - Read more

BioXcel's Igalmi (dexmedetomidine) shows positive Ph3 data for at-home use in schizophrenia, bipolar disorder agitation
Small molecule, neurological, sublingual film, agitation, schizophrenia, bipolar disorder - Read more

THE GOOD
Fundraises

Fund for Science and Technology launches with $500M pledge supporting bioscience research initiatives
Cancer, cell therapy, foundation, immunotherapy, funding organization - Read more

Wugen raises $115M financing for off-the-shelf CAR-T therapy development
Cell therapy, oncology, hematologic malignancies, off-the-shelf, clinical-stage - Read more

THE GOOD
Investments

Nelson Labs expands Wiesbaden facility with new labs for packaging and microbiological testing services for pharma customers
Testing services, pharmaceutical, medical device, laboratory expansion, operational - Read more

AstraZeneca and Eli Lilly potentially planning major biomanufacturing facilities in Virginia, revealed through state incentive documents
Biomanufacturing, strategic, operational, expansion, major investment - Read more

THE GOOD
Market Reports

Global pharmas invest $48.5B in Chinese biotech partnerships during H1 2025, surpassing entire 2024 total
Licensing deal, oncology, China, milestone payments, global partnerships, immunology - Read more

THE GOOD
Mergers & Acquisitions

Eversana and Waltz Health merge to create unified pharmaceutical pricing platform tackling drug costs
Healthcare technology, pharmaceutical services, strategic, major transaction, cost reduction - Read more

THE GOOD
Regulatory

FDA restricts COVID-19 vaccines for youth, approves updated formulations for at-risk individuals
mRNA vaccine, infectious disease, regulatory, operational - Read more

THE GOOD
Strategic Plans

Nykode pivots to phase 2 cancer trial after Genentech exit and staff cuts amid uncertain future
DNA vaccine, head and neck cancer, oncology, strategic, cost reduction, financial - Read more

PRESENTED BY YOU?
Get the attention of 2000+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Clinical Trials

Amylyx discontinues Relyvrio (AMX0035) Ph2/3b program after failed efficacy in progressive supranuclear palsy trial
Small molecule, neurological, rare disease, progressive supranuclear palsy, failed clinical trial - Read more

THE BAD
Layoffs

Exelixis lays off 130 employees, closes Pennsylvania site in restructuring to consolidate operations in California
Small molecule, oncology, operational, cost reduction - Read more

Indivior cuts jobs, considers Opvee divestiture in first phase of restructuring to improve profitability
Small molecule, substance use disorder, operational, cost reduction, strategic, divestiture - Read more

THE BAD
Market Reports

MassBio report reveals Massachusetts biotech employment stagnated with R&D and manufacturing jobs declining in 2024
Biomanufacturing, R&D, employment, operational, financial - Read more

THE BAD
Politcs & Policy

Former FDA Commissioner Gottlieb warns US losing biotech edge to China amid NIH cuts
Healthcare policy, regulatory, strategic, national security, innovation - Read more

THE UGLY
Regulatory

CDC Director Susan Monarez ousted after opposing Kennedy's COVID vaccine restrictions for children
Infectious disease, public health, regulatory, leadership change, policy conflict - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here